Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

FTSE 250 movers: Hikma, Rotork shine, Renishaw slips

Published 28/04/2023, 16:08
© Reuters FTSE 250 movers: Hikma, Rotork shine, Renishaw slips

Sharecast - Specialist engineer Rotork (LON:ROR) said it expected adjusted operating profit to be slightly ahead of expectations driven by strong order intake.

Sales for the three months to April 2 rose 18% against a more supply-chain disrupted comparative period and benefited from both volume and selling price increases, with all divisions and regions ahead year-on-year and with particularly strong growth in the Americas, the company said on Friday.

Order intake was ahead a mid-teen percentage year-on-year on an organic constant currency basis, with all divisions making “encouraging progress”, Rotork said.

“Our orders continue to be driven largely by customers' operational spend. In addition, in the period we saw a return of a relatively high level of large project activity.”

“The outlook for our end markets remains positive and our record order book gives us good visibility into the second half of the year. We are encouraged by the early momentum we are seeing with our growth+ strategy and are investing in the programme as planned. Whilst we are cognisant of the continuing global macro-economic uncertainty, we now expect 2023 adjusted operating profit to be slightly ahead of our earlier expectations.”

Hikma Pharmaceuticals (LON:HIK) upgraded full-year guidance after a stronger-than-expected start to the year for its generics business but expressed concern about the impact of the current conflict in Sudan on operations.

"The safety and wellbeing of our colleagues in Sudan is a top priority and we are doing what we can to support them. Our current guidance does not take into account any potential impact this evolving situation could have on our business. In 2022 sales from Sudan in our branded and injectables businesses represented 2.5% of group revenue," the company said on Friday.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

"We have also had a stronger than expected start in our generics business, leading us to upgrade our guidance for the full year."

Renishaw (LON:RSW) downgraded its full-year outlook on Friday amid lower demand from the semiconductor and electronics sectors.

The company said it now expects full-year revenues of between £680m and £700m, and adjusted pre-tax profit of £135m and £150m. This is down from previous guidance for revenues of £690m to £730m and adjusted pre-tax profit of between £140m and £165m.

In an update for the nine months to the end of March, Renishaw said total revenue rose 6% on the same period a year earlier to £492.4m, while adjusted pre-tax profit fell 10% to £111.8m.

Revenue in the manufacturing technologies segment increased 6% to £496.7m, while revenue in analytical instruments and medical devices was just 1% higher at £25.3m.

Renishaw said: "We expect current market conditions to continue during the remainder of this financial year. We continue to invest in innovative new products and manufacturing capacity to support our growth objectives, whilst managing costs carefully and focusing on productivity."

At 1450 BST, the shares were down 3% at 3,560p.

Jefferies reiterated its 'underperform' rating on the shares after the update. It said: "We believe that market expectations were set low, so this downgrade may not come as a major surprise.

"Our view, however, is that market conditions will continue through the remainder of calendar 2023, and therefore we see DD downgrade risk to FY24F estimates as well, which will pressure the share price."

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

FTSE 250 - Risers

Rotork 327.60p +3.74%

Hikma Pharmaceuticals 1,834.50p +3.64%

Bakkavor Group (LON:BAKK) 99.00p +3.56%

Rathbones Group (LON:RAT) 1,962.00p +3.15%

Genuit Group (LON:GENG) 300.00p +3.09%

CLS Holdings PLC (LON:CLSH) 134.40p +3.07%

Urban Logistics Reit PLC (LON:SHED) 140.40p +2.78%

Dr. Martens PLC (LON:DOCS) 167.30p +2.64%

Crest Nicholson Holdings (LON:CRST) 268.00p +2.52%

Redrow (LON:RDW) 521.00p +2.46%

FTSE 250 - Fallers

W.A.G Payment Solutions (LON:WPS) 95.20p -7.12%

Renishaw (LON:RSW) 3,554.00p -3.42%

Petershill Partners (LON:PHLL) 163.60p -2.50%

Caledonia Investments (LON:CLDN) 3,525.00p -2.22%

Telecom Plus (LON:TEP) 1,824.00p -2.15%

Bank of Georgia Group (LON:BGEO) 2,975.00p -1.98%

Syncona Limited NPV (LON:SYNCS) 155.60p -1.39%

abrdn Private Equity Opportunities Trust plc (LON:APEO) 446.00p -1.33%

Drax Group (LON:DRX) 625.20p -1.23%

4Imprint Group (LON:FOUR) 4,525.00p -1.20%

Read more on Sharecast.com

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.